A new approach to antibody therapy delivery

In 2025, researchers at the MIT developed a new method for delivering therapeutic antibodies more efficiently.

Traditionally, antibody treatments for cancer and autoimmune diseases require lengthy intravenous infusions in hospitals, often lasting several hours.

The MIT team reformulated antibodies into highly concentrated solid microparticles suspended in solution, enabling delivery with a standard syringe rather than the prolonged IV infusion. This approach significantly reduces treatment time and may lessen the burden of hospital visits, particularly for older patients or those with limited mobility.